Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands
Clinical Endocrinology Mar 14, 2018
Kasuki L, et al. - The efficacy and predictors of response and safety of cabergoline (CAB) treatment in acromegaly as monotherapy and in combination with somatostatin receptor ligands (SRLs) were determined. A lower efficacy of CAB in acromegaly compared to other drugs was demonstrated. Treatment escape occurred after a long-term follow-up.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
